港股详情

本页面由Tiger Fintech (Singapore) Pte. Ltd.提供服务

医药外包概念

1,934.376

-4.081-0.21%

涨家数：5

跌家数：3

平家数：- -

市盈率：- -

高：1,954.807

开：1,938.984

低：1,912.599

收：1,938.457

数据加载中...

美股异动丨诺和诺德盘前涨超2% Ozempic获欧盟推荐使用以治疗动脉疾病

【丽珠医药(01513.HK)：YJH-012注射液获批开展临床试验用于治疗痛风适应症】智通财经APP讯，丽珠医药(01

泰格医药06月24日获主力加仓262.3万元

重药控股(000950.SZ)：盐酸普拉格雷片临床试验获受理

智通财经网

健康元(600380.SH)：YJH-012注射液获批开展临床试验

韦恩生物科技有限公司药品申请临床试验默示许可获受理

唯久生物技术（苏州）有限公司药品申请临床试验默示许可获受理

浙江鑫康合生物医药科技有限公司药品申请临床试验默示许可获受理

【港股异动 | 宜明昂科-B(01541.HK)涨超7% IMC-003/IMM72治疗肺动脉高压临床试验获国家药监局批

港股异动 | 宜明昂科-B(01541)涨超7% IMC-003/IMM72治疗肺动脉高压临床试验获国家药监局批准

拨康视云-B(02592.HK)预计7月3日上市引入富策控股及Reynold Lemkins作为基石

安进（Amgen）最新跌幅达7%该公司实验性减肥药的临床试验结果已公布。

药明康德斥资10亿元回购股份并计划注销，和铂医药拿下6.7亿美元BD交易，石药集团美洛昔康注射液首仿获批，百奥泰又一产品出海

英硅智能闯进决赛圈

美股异动 | 诺和诺德一度跌近7%，新减肥药临床试验副作用率近80%

老虎资讯综合

中证沪港深创新药产业指数上涨1.74%，前十大权重包含药明康德等

【药明康德(02359.HK)实施完毕2025年第二次股份回购方案】智通财经APP讯，药明康德(02359.HK)发布公

中源协和(600645.SH)子公司VUM02注射液临床试验申请取得受理通知书

亿帆医药(002019.SZ)：人生长激素注射液临床试验获批准

药明康德：已完成10亿元股份回购并计划注销

国际金融报

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/stock/BK1576/news?page=4"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"BK1576","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BK1576\",,,,,undefined,":{"symbol":"BK1576","market":"HK","secType":"PLATE","nameCN":"医药外包概念","latestPrice":1934.3763,"timestamp":1751007694560,"preClose":1938.4569,"halted":0,"volume":62948517,"delay":0,"changeRate":-0.002105,"floatShares":0,"shares":0,"eps":0,"marketStatus":"交易中","change":-4.080566,"latestTime":"06-27 15:01:38","open":1938.9838,"high":1954.8066,"low":1912.5989,"amount":1558481590,"amplitude":0.021774,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"tradingStatus":0,"nextMarketStatus":{"tag":"收盘","tradingStatus":0,"beginTime":1751011800000},"marketStatusCode":0,"adr":0,"adjPreClose":0,"openAndCloseTimeList":[[1750987800000,1750996800000],[1751000400000,1751011200000]],"pbRate":2.21948,"peRate":10.59865,"turnoverRate":0.005553,"increases":5,"decrements":3,"flats":0,"marketCap":426145906176,"floatMarketCap":179267225728},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BK1576\",,,,,undefined,":{"symbol":"BK1576","high":1954.8066,"amplitude":0.021774,"preClose":1938.4569,"low":1912.5989,"pbRate":"2.21948","latestPrice":1934.3763,"volume":62948517,"delay":0,"open":1938.9838,"prevYearClose":1395.7731,"prevWeekClose":1883.162,"prevMonthClose":1859.052,"prevQuarterClose":1941.338,"fiveDayClose":1883.162,"twentyDayClose":1859.052,"sixtyDayClose":1942.366,"secType":"PLATE","market":"HK","turnoverRate":0.005553,"peRate":10.59865,"marketCap":426289511936,"floatMarketCap":179286577280,"timestamp":1751007694560,"nameCN":"医药外包概念"},"@#url:\"https://hq.skytigris.cn/api/global/plate/up_down\",method:\"POST\",data:#delay:false,bkCodes:@\"BK1576\",,,,undefined,":{"bkCode":"BK1576","up":5,"down":3,"flat":0},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"BK1576\",pageSize:20,pageCount:4,lang_content:\"cn\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2545353404","title":"美股异动丨诺和诺德盘前涨超2% Ozempic获欧盟推荐使用以治疗动脉疾病","url":"https://stock-news.laohu8.com/highlight/detail?id=2545353404","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2545353404?lang=zh_cn&edition=fundamental","pubTime":"2025-06-24 16:55","pubTimestamp":1750755317,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.gelonghui.com/rss/live/live.xml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_gelonghui","symbols":["BK1583","IE00BZ1G4Q59.USD","NVO","BK1576","BK4007","IE00BKVL7J92.USD","03347","BK1141","BK4532","BK4585","LU1093756325.SGD","BK4599","LU0154236417.USD","LU1093756168.USD","BK4588"],"gpt_icon":0},{"id":"2545023401","title":"【丽珠医药(01513.HK)：YJH-012注射液获批开展临床试验用于治疗痛风适应症】智通财经APP讯，丽珠医药(01","url":"https://stock-news.laohu8.com/highlight/detail?id=2545023401","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2545023401?lang=zh_cn&edition=fundamental","pubTime":"2025-06-24 16:52","pubTimestamp":1750755131,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["03347","BK1576","01513","BK1141","BK1583","BK1191"],"gpt_icon":0},{"id":"2545510285","title":"泰格医药06月24日获主力加仓262.3万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2545510285","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2545510285?lang=zh_cn&edition=fundamental","pubTime":"2025-06-24 16:15","pubTimestamp":1750752956,"startTime":"0","endTime":"0","summary":"06月24日, 泰格医药股价涨2.56%，报收38.05元，成交金额1.2亿元，换手率2.54%，振幅4.85%，量比0.79。泰格医药今日主力资金净流入262.3万元，连续4日净流入，上一交易日主力净流入897.8万元。近一年数据显示，该股主力连续4日净流入后，次日上涨概率为77.78%，平均涨幅为1.89%。该股近5个交易日上涨0.53%，主力资金累计净流入2349.0万元，其中2个交易日为股价下跌时净流入；近20日主力资金累计净流入9933.5万元，其中净流入天数为14日。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250624173703a71afa27&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250624173703a71afa27&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1583","03347","BK1576","BK1141"],"gpt_icon":0},{"id":"2545903405","title":"重药控股(000950.SZ)：盐酸普拉格雷片临床试验获受理","url":"https://stock-news.laohu8.com/highlight/detail?id=2545903405","media":"智通财经网","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2545903405?lang=zh_cn&edition=fundamental","pubTime":"2025-06-24 15:45","pubTimestamp":1750751100,"startTime":"0","endTime":"0","summary":"重药控股(000950.SZ)公告，公司控股子公司重庆医药(集团)股份有限公司(简称“重药股份”)收到国家药品监督管理局签发的《受理通知书》，药物名称为：盐酸普拉格雷片。公告显示，盐酸普拉格雷片原研公司为第一三共株式会社，是第三代的抑制ADP激活的血小板聚集的药物，适应于预防接受经皮冠状动脉介入治疗后的急性冠状动脉综合征、稳定型心绞痛，陈旧性心肌梗塞患者的血栓形成。\n\n\n海量资讯、精准解读，尽在新浪财经APP","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/hkstock/ggscyd/2025-06-24/doc-infcefer5629593.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["000950","03347","BK1141","BK0071","BK0250","BK1576","BK1583"],"gpt_icon":0},{"id":"2545403479","title":"健康元(600380.SH)：YJH-012注射液获批开展临床试验","url":"https://stock-news.laohu8.com/highlight/detail?id=2545403479","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2545403479?lang=zh_cn&edition=fundamental","pubTime":"2025-06-24 15:40","pubTimestamp":1750750847,"startTime":"0","endTime":"0","summary":"智通财经APP讯，健康元(600380.SH)公告，公司控股子公司丽珠医药集团股份有限公司(简称：丽珠集团)收到国家药品监督管理局核准签发的《药物临床试验批准通知书》，批准YJH-012注射液开展临床试验(痛风适应症)。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1308895.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1576","BK0077","BK1583","03347","BK0046","BK0028","BK0114","BK0188","600380","BK1141","BK0239"],"gpt_icon":0},{"id":"2545665470","title":"韦恩生物科技有限公司药品申请临床试验默示许可获受理","url":"https://stock-news.laohu8.com/highlight/detail?id=2545665470","media":"金融界","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2545665470?lang=zh_cn&edition=fundamental","pubTime":"2025-06-24 14:51","pubTimestamp":1750747880,"startTime":"0","endTime":"0","summary":"6月24日，据CDE官网消息，韦恩生物科技有限公司联合申请药品“WBD156胶囊”，获得临床试验默示许可，受理号CXHL2500395。公示信息显示，药品“WBD156胶囊”适应症：超重或肥胖症。韦恩生物科技有限公司，成立于2020年，位于上海市，是一家以从事科技推广和应用服务业为主的企业。通过天眼查大数据分析，韦恩生物科技有限公司知识产权方面有商标信息3条，专利信息4条，此外企业还拥有行政许可4个。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.jrj.com.cn/2025/06/24145151262813.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["03347","BK1141","159837","BK1576","BK1583"],"gpt_icon":0},{"id":"2545470624","title":"唯久生物技术（苏州）有限公司药品申请临床试验默示许可获受理","url":"https://stock-news.laohu8.com/highlight/detail?id=2545470624","media":"金融界","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2545470624?lang=zh_cn&edition=fundamental","pubTime":"2025-06-24 14:51","pubTimestamp":1750747880,"startTime":"0","endTime":"0","summary":"6月24日，据CDE官网消息，唯久生物技术（苏州）有限公司联合申请药品“VS-2218固体分散体片”，获得临床试验默示许可，受理号CXHL2500369。唯久生物技术（苏州）有限公司，成立于2021年，位于苏州市，是一家以从事医药制造业为主的企业。主要股东信息显示，唯久生物技术（苏州）有限公司由唯久生物有限公司持股100%。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.jrj.com.cn/2025/06/24145151262811.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["BK1141","BK1583","BK1576","03347"],"gpt_icon":0},{"id":"2545470616","title":"浙江鑫康合生物医药科技有限公司药品申请临床试验默示许可获受理","url":"https://stock-news.laohu8.com/highlight/detail?id=2545470616","media":"金融界","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2545470616?lang=zh_cn&edition=fundamental","pubTime":"2025-06-24 14:51","pubTimestamp":1750747880,"startTime":"0","endTime":"0","summary":"6月24日，据CDE官网消息，浙江鑫康合生物医药科技有限公司、北京鑫康合生物医药科技有限公司联合申请药品“XKH001注射液”，获得临床试验默示许可，受理号CXSL2500291。浙江鑫康合生物医药科技有限公司，成立于2015年，位于绍兴市，是一家以从事研究和试验发展为主的企业。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.jrj.com.cn/2025/06/24145151262812.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["BK1583","399441","BK1576","BK1141","03347","161726"],"gpt_icon":0},{"id":"2545478432","title":"【港股异动 | 宜明昂科-B(01541.HK)涨超7% IMC-003/IMM72治疗肺动脉高压临床试验获国家药监局批","url":"https://stock-news.laohu8.com/highlight/detail?id=2545478432","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2545478432?lang=zh_cn&edition=fundamental","pubTime":"2025-06-24 10:29","pubTimestamp":1750732186,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["01541","BK1576","BK1141","BK1583","BK1161","03347"],"gpt_icon":0},{"id":"2545478430","title":"港股异动 | 宜明昂科-B(01541)涨超7% IMC-003/IMM72治疗肺动脉高压临床试验获国家药监局批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2545478430","media":"智通财经","labels":["productRelease","movement"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2545478430?lang=zh_cn&edition=fundamental","pubTime":"2025-06-24 10:29","pubTimestamp":1750732186,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，宜明昂科-B(01541)涨超7%，截至发稿，涨7.05%，报13.36港元，成交额1520.04万港元。消息面上，6月23日，宜明昂科-B发布公告，该集团获得中国国家药品监督管理局(“国家药监局”)有关启动IMC-003/IMM72治疗肺动脉高压(PAH) 的临床试验的新药临床试验(IND)批准。据介绍，IMC-003/IMM72为通过基因改造的新一代启动素受体IIA-Fc型(ActRIIA-Fc)融合蛋白，具有更高的活性及品质。集团拥有IMC-003/IMM72的全球知识产权以及开发及商业化权利。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1308786.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease,movement","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["01541","03347","BK1141","BK1583","BK1576","BK1161"],"gpt_icon":0},{"id":"2545342376","title":"拨康视云-B(02592.HK)预计7月3日上市 引入富策控股及Reynold Lemkins作为基石","url":"https://stock-news.laohu8.com/highlight/detail?id=2545342376","media":"格隆汇","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2545342376?lang=zh_cn&edition=fundamental","pubTime":"2025-06-24 06:47","pubTimestamp":1750718838,"startTime":"0","endTime":"0","summary":"格隆汇6月24日丨拨康视云-B发布公告，公司拟全球发售6058.2万股股份，中国香港发售股份605.85万股，国际发售股份5452.35万股；2025年6月24日至6月27日招股；发售价将为每股发售股份10.10港元，每手买卖单位为500股，建银国际及华泰国际为联席保荐人；预期股份将于2025年7月3日开始在联交所买卖。集团拥有两款核心产品，均为自主开发。基石投资者包括富策控股有限公司及The Reynold Lemkins Group  Limited。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.jrj.com.cn/2025/06/24064751250137.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["BK1141","BK1576","02592","03347","BK1583"],"gpt_icon":0},{"id":"2545444394","title":"安进（Amgen）最新跌幅达7%该公司实验性减肥药的临床试验结果已公布。","url":"https://stock-news.laohu8.com/highlight/detail?id=2545444394","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2545444394?lang=zh_cn&edition=fundamental","pubTime":"2025-06-24 02:54","pubTimestamp":1750704865,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["IE00B4R5TH58.HKD","BK4585","LU0320765992.SGD","LU0289739699.SGD","IE0002141913.USD","AMGN","SG9999001440.SGD","BK4581","IE00BJT1NW94.SGD","IE00BFTCPJ56.SGD","BK1583","BK4139","LU1057294990.SGD","LU0122379950.USD","LU1023059063.AUD","BK4599","LU2242652126.USD","03347","LU1983299246.USD","LU1571399168.USD","BK4533","IE00BJJMRZ35.SGD","BK4566","LU2242646821.SGD","BK4588","LU2089984988.USD","LU0889565916.HKD","IE0009355771.USD","BK4534","LU0058720904.USD","LU2468319806.SGD","LU0109394709.USD","IE00B2B36J28.USD","BK1576","LU1061106388.HKD","LU0868494617.USD","LU2112291526.USD","BK1141"],"gpt_icon":0},{"id":"2545445973","title":"药明康德斥资10亿元回购股份并计划注销，和铂医药拿下6.7亿美元BD交易，石药集团美洛昔康注射液首仿获批，百奥泰又一产品出海","url":"https://stock-news.laohu8.com/highlight/detail?id=2545445973","media":"谈医说药","labels":["shareholding","corporation","buyback"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2545445973?lang=zh_cn&edition=fundamental","pubTime":"2025-06-23 23:40","pubTimestamp":1750693230,"startTime":"0","endTime":"0","summary":"截至公告披露日，中国医药投资有限公司持有公司股份105,492,487股，占公司有表决权股份比例的18.04%。划转后，九龙江集团仍持有公司307,522,643股，占总股本50.97%，漳龙集团持股增至1.17%。药明康德：公司已完成2025年第二次股份回购，实际回购股数为1577.54万股，占总股本的0.5462%。公司将于2025年6月24日在中国证券登记结算有限责任公司上海分公司注销本次回购股份方案项下回购的股份，并及时办理变更登记手续等相关事宜。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250623234135a71936a3&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250623234135a71936a3&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding,corporation,buyback","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["IE00BZ08YT58.USD","LU0320764599.SGD","02359","IE0008369823.USD","LU1226288253.USD","LU0880133367.SGD","LU1008478684.HKD","LU1951186391.HKD","IE00BZ08YR35.GBP","02142","BK1574","01093","LU1226287529.USD","LU0067412154.USD","LU0072913022.USD","LU1152091168.USD","SG9999004220.SGD","LU1226287875.USD","BK1521","BK1576","BK1161","LU1046422090.SGD","LU0326950275.SGD","LU0140636845.USD","LU0052750758.USD","BK1515","LU1226288170.HKD","LU1993786604.SGD","LU2125910500.SGD","IE0008368742.USD","BK1141","IE00BZ08YS42.EUR","BK1583","LU1152091754.HKD","IE00B031HY20.USD","LU1960683339.HKD","LU0501845795.SGD","LU2045819591.USD","LU1807302812.USD","LU0708995583.HKD","LU1226287792.SGD","IE00B543WZ88.USD","LU2242644610.SGD","BK1191","IE00B5MMRT66.SGD"],"gpt_icon":0},{"id":"2545644773","title":"英硅智能闯进决赛圈","url":"https://stock-news.laohu8.com/highlight/detail?id=2545644773","media":"虎嗅APP","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2545644773?lang=zh_cn&edition=fundamental","pubTime":"2025-06-23 22:38","pubTimestamp":1750689480,"startTime":"0","endTime":"0","summary":"英硅智能近日宣布其在研肺纤维化药物2a期临床试验数据积极，该药也一跃成为全球进展最快的AI药物。英硅智能联合首席执行官兼首席科学家任峰告诉虎嗅。按照英硅智能的计划，今年他们将与中国药品审评审批部门沟通，争取可以直接将研究推向临床三期。对于英硅智能来说，接下来的挑战也会更加艰巨。英硅智能目前有超过30个研发管线，获得批准进入临床的项目就有10个。客观来说，英硅智能此次公布的2a期临床试验确实存在瑕疵。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://mp.weixin.qq.com/s?__biz=MTQzMjE1NjQwMQ==&mid=2656101021&idx=2&sn=a326ffb12f26e9b99990638b3bf882e9&chksm=6742083b41e26330b81f8864e2e27230c468342d40cd6790b3e2c3fcc2d9778ea4d894027ec4&scene=0#rd","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"weixin_highlight","symbols":["BK1576","BK1574","BK1583","BK1191","01477","03347","BK1141"],"gpt_icon":0},{"id":"1109100784","title":"美股异动 | 诺和诺德一度跌近7%，新减肥药临床试验副作用率近80%","url":"https://stock-news.laohu8.com/highlight/detail?id=1109100784","media":"老虎资讯综合","labels":["dataReport","movement"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1109100784?lang=zh_cn&edition=fundamental","pubTime":"2025-06-23 22:07","pubTimestamp":1750687644,"startTime":"0","endTime":"0","summary":"本周一（6月23日）美股盘前时段， $诺和诺德(NVO)$ 跌幅扩大至近6%，截至发稿报69.42美元：消息面上， 当地时间6月22日，诺和诺德披露其新型减肥药物CagriSema两项三期临床试验完整数据，显示该药物在减重效果和代谢指标改善方面表现积极，但胃肠道副作用发生率高于安慰剂组，未能完全达到资本市场预期。","market":"us","thumbnail":"https://static.tigerbbs.com/85675909dc6c67ee0181339c18bcfdff","type":0,"news_type":0,"thumbnails":["https://static.tigerbbs.com/85675909dc6c67ee0181339c18bcfdff"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"ff5e28b862d1ee6848a739ae092247ea","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"-2","news_top_title":"美股异动 | 诺和诺德一度跌近7%，新减肥药临床试验副作用率近80%","news_tag":"dataReport,movement","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00BKVL7J92.USD","LU0154236417.USD","BK1576","BK1583","BK4588","NVO","BK4599","IE00BZ1G4Q59.USD","LU1093756325.SGD","BK4585","BK4007","LU1093756168.USD","BK1141","BK4532"],"gpt_icon":1},{"id":"2545414657","title":"中证沪港深创新药产业指数上涨1.74%，前十大权重包含药明康德等","url":"https://stock-news.laohu8.com/highlight/detail?id=2545414657","media":"金融界","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2545414657?lang=zh_cn&edition=fundamental","pubTime":"2025-06-23 20:35","pubTimestamp":1750682128,"startTime":"0","endTime":"0","summary":"金融界6月23日消息，上证指数低开高走，中证沪港深创新药产业指数 上涨1.74%，报1934.23点，成交额257.49亿元。数据统计显示，中证沪港深创新药产业指数近一个月上涨5.52%，近三个月上涨6.54%，年至今上涨22.19%。从中证沪港深创新药产业指数持仓样本的行业来看，医药卫生占比100.00%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250623204224978b4476&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250623204224978b4476&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LU0708995583.HKD","LU1046422090.SGD","06978","02359","603259","LU2045819591.USD","LU2125910500.SGD","BK1574","BK1576","BK1583","BK1141","LU0052750758.USD","LU2242644610.SGD","BK1161","LU0320764599.SGD"],"gpt_icon":0},{"id":"2545155234","title":"【药明康德(02359.HK)实施完毕2025年第二次股份回购方案】智通财经APP讯，药明康德(02359.HK)发布公","url":"https://stock-news.laohu8.com/highlight/detail?id=2545155234","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2545155234?lang=zh_cn&edition=fundamental","pubTime":"2025-06-23 18:58","pubTimestamp":1750676299,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["LU1997245094.SGD","LU2488822045.USD","CNHmain","LU0456842615.SGD","LU2242644610.SGD","MCNHmain","MUCmain","02359","BK1576","399300","BK1583","603259","159982","UCmain","LU1997245177.USD","LU2045819591.USD","LU2328871848.SGD","LU1969619763.USD","LU2495084118.USD","LU0320764599.SGD","CYB","LU1997244956.HKD","LU0052750758.USD","BK0216","LU2125910500.SGD","BK1141","LU1046422090.SGD","LU0708995583.HKD"],"gpt_icon":0},{"id":"2545189454","title":"中源协和(600645.SH)子公司VUM02注射液临床试验申请取得受理通知书","url":"https://stock-news.laohu8.com/highlight/detail?id=2545189454","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2545189454?lang=zh_cn&edition=fundamental","pubTime":"2025-06-23 18:11","pubTimestamp":1750673464,"startTime":"0","endTime":"0","summary":"智通财经APP讯，中源协和(600645.SH)发布公告，公司全资子公司武汉光谷中源药业有限公司于2025年6月23日取得国家药品监督管理局药品审评中心(CDE)签发的关于VUM02注射液临床试验申请《受理通知书》，受理号为CXSL2500507。VUM02注射液(人脐带源间充质基质细胞注射液)是我司自主研发的冷冻保存型细胞制剂，是由经筛选的健康新生儿脐带组织通过体外分离、扩增、收获、冻存后制备的人脐带源间充质基质细胞(UC-MSC)新药，临床拟用适应症增加重型/危重型肺炎的治疗。截至公告日，全球尚未有用于治疗重型/危重型肺炎的同类细胞药物上市，研发进展最快的同类药物处于临床试验阶段。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1308482.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0216","600645","03347","BK0046","BK0239","BK0042","BK1141","BK1576","BK1583","BK0188"],"gpt_icon":0},{"id":"2545141898","title":"亿帆医药(002019.SZ)：人生长激素注射液临床试验获批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2545141898","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2545141898?lang=zh_cn&edition=fundamental","pubTime":"2025-06-23 18:08","pubTimestamp":1750673301,"startTime":"0","endTime":"0","summary":"智通财经APP讯，亿帆医药(002019.SZ)公告，公司全资子公司亿帆医药(上海)有限公司于近日收到国家药品监督管理局核准签发的《药物临床试验批准通知书》，药品名称为：人生长激素注射液，国家药品监督管理局同意按生物类似药要求开展临床试验。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1308480.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["002019","03347","BK0197","BK0077","BK0070","BK1583","BK1141","BK0191","BK0239","BK0185","BK1576"],"gpt_icon":0},{"id":"2545549700","title":"药明康德：已完成10亿元股份回购并计划注销","url":"https://stock-news.laohu8.com/highlight/detail?id=2545549700","media":"国际金融报","labels":["shareholding","buyback"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2545549700?lang=zh_cn&edition=fundamental","pubTime":"2025-06-23 17:42","pubTimestamp":1750671750,"startTime":"0","endTime":"0","summary":"药明康德公告，公司已完成2025年第二次股份回购，实际回购股数为1577.54万股，占总股本的0.5462%。回购最高价格人民币69.87元/股，回购最低价格人民币52.52元/股，回购均价人民币63.39元/股，回购金额约为10亿元。公司将于2025年6月24日在中国证券登记结算有限责任公司上海分公司注销本次回购股份方案项下回购的股份，并及时办理变更登记手续等相关事宜。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250623174313978b14c1&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250623174313978b14c1&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding,buyback","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LU1046422090.SGD","LU2045819591.USD","LU0708995583.HKD","LU2125910500.SGD","LU0052750758.USD","LU0320764599.SGD","BK1141","LU2242644610.SGD","02359","BK1583","BK1576"],"gpt_icon":0}],"pageSize":20,"totalPage":12,"pageCount":4,"totalSize":222,"code":"91000000","status":"200"}]}}